<DOC>
	<DOCNO>NCT02420938</DOCNO>
	<brief_summary>The goal clinical research study learn urelumab give combination rituximab help control CLL SLL . The safety drug combination also study .</brief_summary>
	<brief_title>Urelumab ( CD137 mAb ) With Rituximab Relapsed , Refractory High-risk Untreated Chronic Lymphocytic Leukemia ( CLL ) Patients</brief_title>
	<detailed_description>Study Drug Administration : If find eligible take part study , receive rituximab vein 4-6 hour Days 1 , 8 , 15 , 22 , 43 , 64 84 day ( 12 week ) cycle . You receive urelumab vein 1 hour Days 2 , 23 , 44 , 65 cycle . There 2-week period study cycle . Study Visits : On Days 1 , 8 , 15 , 22 , 43 , 64 cycle : - Blood ( 2 tablespoon ) draw routine test . - You physical exam . On Days 2 , 29 , 36 , 50 , 57 , 71 , 78 cycle , blood ( 2 tablespoon ) draw routine test . At end cycle ( Day 85 ) : - Blood ( 2 tablespoon ) draw routine test . - You physical exam . - You bone marrow aspiration biopsy check status disease . - You CT PET scan check status disease . You blood draw , CT scan ( PET scan ) and/or bone marrow aspiration biopsy time doctor think need study . Length Study : You may receive 2 cycle study drug . However , study doctor may allow receive study drug beyond Cycle 2 . You longer able take study drug disease get bad , intolerable side effect occur , unable follow study direction . Your participation study follow-up visit . End-of-Study Visit : If take study reason , follow test procedure perform : - You physical exam . - Blood ( 2-3 tablespoon ) draw routine test . - If doctor think need , bone marrow aspirate CT PET scan check status disease . Long-Term Follow-Up : After long study , 1 time every month : - You physical exam . - Blood ( 2-3 tablespoon ) draw routine test . Every 3 month , doctor think need , bone marrow aspirate CT PET scan check status disease . Other Testing : The study staff may ask take part MD Anderson clinical research study ( PA13-0291 ) additional research testing . The study doctor discus , decide take part , sign separate consent document . This investigational study . Urelumab FDA approve commercially available . Rituximab FDA approve commercially available treatment patient CLL . The use drug combination investigational . The study doctor explain drug design work . Up 24 participant enrol study . All take part MD Anderson .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>1 . Patients diagnosis CLL SLL meet one criterion active disease define International Working Group CLL ( IWCLL ) relapse and/or refractory least one prior therapy . 2 . Age 18 year old . 3 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status &lt; /= 2 . 4 . Patients must adequate renal hepatic function : Serum bilirubin &lt; /= 1.5 x upper limit normal ( ULN ) . For patient Gilbert 's disease , serum bilirubin &lt; /= 3 x ULN allow provide normal direct bilirubin , Serum creatinine &lt; /= 1.5 x ULN , ALT AST &lt; /= 3 x ULN . 5 . Females childbearing potential must negative serum urine beta human chorionic gonadotrophin ( BetahCG ) pregnancy test result within 24 hour prior first dose treatment must agree use effective contraception method study 12 month follow last dose study drug . Females non childbearing potential postmenopausal great 1 year bilateral tubal ligation hysterectomy . Males partner childbearing potential must agree use effective contraceptive method study 31 week follow last dose study drug . Acceptable method contraception condom contraceptive foam ; oral , implantable injectable contraceptive ; contraceptive patch ; intrauterine device ; diaphragm spermicidal gel ; sexual partner surgically sterilize postmenopausal . 6 . Patients legally authorize representative must provide write informed consent . 1 . Prior malignancy active within previous 2 year except locally curable cancer apparently cure , basal squamous cell skin cancer , superficial bladder cancer , carcinoma situ cervix breast , localized prostate cancer . If patient another malignancy treat within last 2 year , patient may enrol likelihood require systemic therapy malignancy within 2 year less 10 % , determine expert particular malignancy MD Anderson Cancer Center consultation Principal Investigator 2 . Any major surgery , radiotherapy , chemotherapy , biologic therapy , immunotherapy , experimental therapy within 4 week prior first dose study drug . For oral targeted therapy ( ibrutinib , idelalisib , venetoclax ) , washout 3 day allow . Note : Prior treatment anti CD20 monoclonal antibody , anti CD52 monoclonal antibody lenalidomide allow . Prior treatment antiCTLA4 antiPD1 therapy allow washout 5 halflives . 3 . Significant cardiovascular disease uncontrolled symptomatic arrhythmia , ( thirddegree AV block , ventricular tachycardia , atrial fibrillation rapid ventricular rate ( HR &gt; 100 bpm ) ) , congestive heart failure , myocardial infarction within 2 month screen , Class 3 4 cardiac disease define New York Heart Association Functional Classification . 4 . History stroke cerebral hemorrhage within 2 month . 5 . Patients uncontrolled hypertension ( define sustain systolic blood pressure &gt; /= 160 mmHg diastolic &gt; /= 100 mmHg ) . 6 . Known evidence active cerebral/meningeal CLL . Patients may history CNS leukemic involvement definitively treat prior therapy evidence active disease time registration . 7 . Known active , uncontrolled autoimmune hemolytic anemia immune thrombocytopenia require steroid therapy . 8 . Patients autoimmune disease exclude : Patients history Inflammatory Bowel Disease ( include Crohn 's disease ulcerative colitis ) exclude study patient history autoimmune disease ( e.g. , rheumatoid arthritis , systemic progressive sclerosis , systemic lupus erythematosus , Wegener 's granulomatosis ) . 9 . Patients previous allogeneic stem cell transplant ( SCT ) within 6 month active acute chronic graftversus host disease exclude . Patients must immunosuppression GVHD least 30 day cycle 1 day 1 . 10 . Patients organ allograft ( renal transplant ) exclude . 11 . History hepatitis ( e.g. , alcohol nonalcohol steatohepatitis ( NASH ) , auto immune , grade 34 drugrelated hepatitis ) . 12 . Patients highdose steroid ( dos &gt; 10mg/day prednisone equivalent ) immune suppression medication . Note : Patients highdose steroid ( dos &gt; 10mg/day prednisone equivalent ) immune suppression medication eligible provide drug discontinue least 3 day prior start study drug . 13 . Patients uncontrolled active infection ( viral , bacterial , fungal ) eligible . 14 . Current chronic hepatitis B C infection , know seropositivity HIV . Note : Patients previous history Hepatitis B ( clear infection natural immunity , i.e . Hep B core antibody positive case ) exclude prophylaxis Hep B reactivation antiviral agent ( entecavir ) recommend , consultation gastroenterologist/hepatologist infectious disease team . 15 . Patient pregnant breastfeeding . 16 . Concurrent use investigational therapeutic agent . 17 . Patients may receive concurrent chemotherapy , radiotherapy , immunotherapy . Localized radiotherapy area compromise bone marrow function apply . 18 . Other severe acute chronic medical psychiatric condition laboratory abnormality opinion investigator may increase risk associate study participation investigational product administration may interfere interpretation study result and/or would make patient inappropriate enrollment study . 19 . Patients Richter 's transformation allow study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>CLL</keyword>
	<keyword>Small Lymphocytic Lymphoma</keyword>
	<keyword>SLL</keyword>
	<keyword>Refractory/relapsed</keyword>
	<keyword>High-risk molecular feature</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Rituxan</keyword>
	<keyword>Urelumab</keyword>
</DOC>